Funding sources None Declared
European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma
Version of Record online: 26 NOV 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 5, pages 536–544, May 2013
How to Cite
Morton, C.A., Szeimies, R.-M., Sidoroff, A. and Braathen, L.R. (2013), European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 27: 536–544. doi: 10.1111/jdv.12031
Conflict of interest CA Morton has received speaker honoraria from Galderma and served as a consultant to Almirall and Leo Pharma. RM Szeimies has served as a consultant for, and has received speakers' honoraria and financial support to perform clinincal trials from Almirall, Biofrontera, Galderma, Leo, photonamic and Spirig. The other authors declare no conflicts of interest. [Correction added on 30 November 2012, after first online publication: conflict of interest statement was amended.]
Disclaimer The following guidelines are based on the best evidence available at the time of publication and caution should be exercised when interpreting data where there is a limited evidence base. It may be necessary to depart from the guidelines in the interests of specific patients and circumstances.
- Issue online: 10 APR 2013
- Version of Record online: 26 NOV 2012
- Received: 27 June 2012; Accepted: 03 October 2012
- 7Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol2007; 157: 87–91., .
- 8Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol2006; 5: 642–645., , , .
- 9Photodynamic therapy with BF-200 ALA for the treatment of actinic keratoses: results of a multicentre, randomized, observer-blind phase III study in comparison with registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol2012; 166: 137–146., , et al.
- 13The use of photodynamic therapy in Dermatology: results of a consensus conference. J Drugs Dermatol2006; 5: 140–154., , et al.
- 25Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blind study. Br J Dermatol2008; 158: 740–746., , et al.
- 26A randomized, multicentre study of directed daylight exposure times of 1 1/2 vs. 2 1/2 h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol2011; 164: 1083–1090., , et al.
- 46Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol2006; 155: 1029–1036. Morton CA. Guidelines for topical photodynamic therapy 2008, , et al.
- 47The Phase IV ALA-PDT Actinic Keratosis Study Group. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol2006; 155: 1262–9., , , et al.
- 53Guidelines on actinic keratosis. European Dermatology Forum: http://www.euroderm.org/edf/images/stories/guidelines/guideline_Management_Actinic_Keratoses-update2011.pdf., , . et al.
- 55A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. Br J Dermatol2011; 164: 429–433., , et al.
- 59Photodynamic therapy in the treatment of extensive Bowen’s disease. J Dermatolog Treat2011. doi: 10.3109/09546634.2011.590789. [Epub ahead of print]., , et al.
- 62Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol2008; 18: 547–553., , et al.
- 74Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient’s satisfaction and reduces the need for surgical procedures. J Eur Acad Dermatol Venereol2011; 25: 861–864., , et al.
- 79Predictors of pain associated with photodynamic therapy: a retrospective study of 658 treatments. Acta Derm Venereol2011; 91: 545–551., , et al.
- 86Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol2006; 154: 146–149., .
- 92Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone. Br J Dermatol2009; 161: 353–356., , et al.